INTRODUCTION
Renal oncocytoma (RO) and chromophobe renal cell carcinoma (ChRCC) are both renal epithelial neoplasms thought to arise from intercalated cells of collecting ducts. Together they account for approximately 10% of surgically removed renal epithelial tumors (4) .
Oncocytomas are benign, nonencapsulated neoplasms composed of round-to-polygonal cells with densely granular eosinophilic cytoplasm (so-called oncocytes), which form compact nests, acini, tubules or microcysts. Oncocytomas occasionally have sclerosed central area (4, 14) . ChRCC are solid tumors made up of large polygonal cells with prominent cell membranes, pale cytoplasm and usually a perinuclear halo. They include three subtypes:
classic, eosinophilic and mixed (24). The majority of ChRCCs are stage T1 and T2 and only a few cases of lymph node and distant metastasis have been described (4) .
Distinction between RO and ChRCC, especially its eosinophilic variant, can sometimes be difficult due to their overlapping morphological characteristics. Histology, ultrastructural examination and staining with Hale's colloidal iron can be used for their differentiation in daily practice. In recent years, there have been attempts to find an immunohistochemical marker that could also help in diagnostics (1, 5, (15) (16) (17) 19 ).
Cancer testis antigens (CTAs) comprise a family of more than 40 genes expressed in a wide variety of malignant tumors (21). In normal tissue, their expression is mostly limited to germ cell lines. Because of their ability to induce immune responses, CTAs are being evaluated as targets for therapeutic cancer vaccines (3, 23) . were females and 7 males. Patients' age ranged from 34-76 years (mean 58.2). Tumor size ranged from 1.7-17cm (mean 7.6).
IMMUNOHISTOCHEMISTRY
Two antibodies were used for immunohistochemical staining. 57B was generated on immunization of mice with recombinant MAGE-A3 (13) . However, this antibody recognizes a variety of MAGE-A molecules and it is currently considered a multi-MAGE-A-specific reagent (11). D8.38 antibody, recognizing NY-ESO-1 and its homologous LAGE-1 CTA, has been previously described (22).
Tissue sections of 3 to 5 µm thickness were cut from paraffin-embedded tissue blocks, placed on object slides (Menzel-Glaser, Germany) and incubated for 20 minutes in a thermostat at 
STATISTICAL ANALYSIS
Statistical analysis was done using Mann-Whitney and Spearman's rank correlation tests. P < 0.05 was considered to be statistically significant. Tables 1 and 2 . Fifteen ROs (88.2%) were positive for both MAGE-A3/4 and NY-ESO-1 antigens (Fig 1A and B) . Regarding ChRCC, 7 (38.9%) showed positive reaction for MAGE-A3/4 antigen and 6 (33.3%) for NY-ESO-1 antigen (Fig 1C and D However, the expression of both CTAs was significantly higher in RO compared to ChRCC.
Nevertheless, additional research is needed to clarify their potential diagnostic implications. 
